Breaking News, Collaborations & Alliances

Esperion, Daiichi Sankyo Report $125M Amendment to Collaboration

Includes transfer of certain manufacturing and supply rights to Daiichi Sankyo Europe and expansion of collaboration in Europe.

Esperion Therapeutics, Inc. and Daiichi Sankyo Europe GmbH (DSE), the European organization of Daiichi Sankyo Co., reported a $125 million amendment to their collaboration, which includes a resolution to their commercial dispute and certain other adjustments to enhance the long-term value of their products. DSE has agreed to pay Esperion $100 million ahead of an anticipated Type II(a) variation approval by the European Medicines Agency (EMA) for NILEMDO (bempedoic acid) Tablet and NUSTENDI (b...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters